tozorakimab

From Aaushi

Jump to navigation Jump to search

^[1]

Indications

investigational treatment of moderate-severe COPD exacerbation

More general terms

References

↑ AstraZeneca Tozorakimab met primary endpoint in both OBERON and TITANIA Phase III trials in patients with COPD. AstraZeneca. March 27, 2026 https://www.astrazeneca.com/media-centre/press-releases/2026/tozorakimab-met-primary-endpoint-in-oberon-titania-phase-iii-trials-in-patients-with-copd.html

Retrieved from "https://aaushi.info/w/index.php?title=A59529&oldid=1292089"

↑ Back to top